DRIVIN G ROWTH - Dr. Reddy's

More documents

Recommendations

Info

<strong>Dr</strong>. Reddy’s drug discovery program is at the heart of its vision—to be a global, discovery-led major. With 260 scientists focussed exclusively on discovery research, 23 patents, and a 9 molecule pipeline, it has built an array of discovery skills. The Research Foundation in India has world-class chemistry and strong pharmacology skills. Its Atlanta, USA lab focuses on early stage research skills, like target identification and high throughput screening. Aurigene, a discovery services unit, adds automated medicinal chemistry and structure-based drug design to the mix. 1994 Commenced: <strong>Dr</strong>ug discovery in metabolic disorders, cancer, inflammation & bacterial infections; one of the first Indian companies to do so discovery research 1995 Filed: Our first patent application in the US for antidiabetic & anti-cancer molecules; currently 67 patents filed; 23 granted 1997 Out-licensed: Balaglitazone (DRF 2593), our first insulin sensitizer, to Novo Nordisk; the first from India
1997 Entered: Phase I clinical trials, Balaglitazone (DRF 2593) 1998 Out-licensed: Ragaglitazar (DRF 2725), our second insulin sensitizer, to Novo Nordisk 2001 Entered: Phase III clinical trials, Ragaglitazar; the first molecule in its class to enter this stage. 2000 Entered: Phase II clinical trials, Balaglitazone and Ragaglitazar 1999 Entered: Phase I clinical trial, Ragaglitazar (DRF 2725) 1999 Established: Atlanta US facility for target-based drug discovery 2001 Out-licensed: DRF 4158, first in class insulin sensitizer to Novartis Established: Aurigene, a discovery services company in Bangalore; for structurebased drug design 2000 Commenced: In-house Phase I clinical trials for DRF 1042 (anti-cancer); first time in India
Page 1 and 2: DRIVIN G ROWTH Dr. Reddy’s Labora
Page 3 and 4: sales of branded formulations grew
Page 5 and 6: THE ULTIMATE ACCOLADE FOR A PHARMAC
Page 7: IT TAKES COURAGE AND VISION TO LOOK
Page 11 and 12: 1987 USFDA Inspection: Ibuprofen fa
Page 13 and 14: 1999 Submitted: ANDA for Omeprazole
Page 15 and 16: 1995 Established: Reddy- Biomed; ou
Page 17 and 18: ARMED WITH A HIGHLY MOTIVATED AND C
Page 19 and 20: K ILO L AB FACILITY at Technology D
Page 21 and 22: SHE PRACTICES HAVE EVOLVED FROM AN
Page 23 and 24: ADOPTING A COMPETENCY-BASED FRAMEWO
Page 25 and 26: THE HIGHEST PATRIOTISM AND PHILANTH
Page 27 and 28: AFTER AN HOUR AT ROSHNI I LEFT WITH
Page 29 and 30: and valuation THE DICTUM in any kno
Page 31 and 32: total shareholder’s return “TOT
Page 33 and 34: 4,585,070 equity shares of erstwhil
Page 35 and 36: REDDY PHARMACEUTICALS HONG KONG LTD
Page 37 and 38: Pathway enables Reddy US Therapeuti
Page 39 and 40: AUDITORS THE AUDIT in the financial
Page 41 and 42: 2.Benefits derived as a result of t
Page 43 and 44: Table B | Technology, absorption, a
Page 45 and 46: articulation of its corporate visio
Page 47 and 48: THE LAUNCH OF FLUOXETINE HAS BEEN T
Page 49 and 50: MUCH OF THE CASH FLOW ARISING OUT O
Page 51 and 52: WITH THE ANTICIPATED GROWTH IN THE
Page 53 and 54: CHART B NCE Pipeline Diabetes DRF N
Page 55 and 56: AURIGENE WILL BUILD SKILLS IN AUTOM
Page 57 and 58: The highlights of the scheme were:
Page 59 and 60:
INVESTMENTS INVESTMENTS reduced to
Page 61 and 62:
Rs. 108 million (US$ 2.25 million)
Page 63 and 64:
THE STRENGTH OF INDIA’S SCIENTIFI
Page 65 and 66:
internal accounting, administrative
Page 67 and 68:
e disproportionately distributed in
Page 69 and 70:
COMPOSITION AND MEETINGS OF THE BOA
Page 71 and 72:
Table 2 | Remuneration of the direc
Page 73 and 74:
(iii) Ms. G Anuradha (daughter of D
Page 75 and 76:
increase speed of reporting and cre
Page 77 and 78:
the Committee. The Investment Commi
Page 79 and 80:
MANAGEMENT DISCUSSION AND ANALYSIS
Page 81 and 82:
non-executive, independent Addition
Page 83 and 84:
press releases and conducts program
Page 85 and 86:
We state that no investor grievance
Page 87 and 88:
Media Bhaswati Banerjee / R. Rammoh
Page 89 and 90:
CODES AT VARIOUS STOCK EXCHANGES Th
Page 91 and 92:
EQUITY HISTORY OF THE COMPANY Table
Page 93 and 94:
SHAREHOLDING PATTERN AS ON MARCH 31
Page 95 and 96:
dematerialised form may contact the
Page 97 and 98:
UNCLAIMED DIVIDENDS Pursuant to sec
Page 99 and 100:
generics Survey No. 41 Bachupally Q
Page 101 and 102:
financials 103
Page 103 and 104:
annexure to the auditors’ report
Page 105 and 106:
alance sheet | AS AT MARCH 31 (All
Page 107 and 108:
schedules to the balance sheet | (A
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
schedules to the profit and loss ac
Page 119 and 120:
schedule to the balance sheet and p
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
cash flow statement | YEAR ENDED MA
Page 133 and 134:
auditors’ certificate To The Boar
Page 135 and 136:
consolidated financials
Page 137 and 138:
consolidated balance sheet | (All a
Page 139 and 140:
schedules to the consolidated balan
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
schedules to the consolidated profi
Page 147 and 148:
schedule to the consolidated balanc
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
cash flow statement | (contd...) YE
Page 163 and 164:
statement under section 212
Page 165 and 166:
The net Aggregate of profits (losse
Page 167 and 168:
drl investments ltd.
Page 169 and 170:
auditors’ report A RAMACHANDRA RA
Page 171 and 172:
alance sheet | AS Schedule 2002 200
Page 173 and 174:
schedules | AS AT MARCH 31 (Rs) 200
Page 175 and 176:
schedules Schedule - 3.00 NOTES TO
Page 177 and 178:
compact electric ltd.
Page 179 and 180:
Page 181 and 182:
alance sheet | AS Schedule 2002 200
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
schedules | FOR THE YEAR ENDED MARC
Page 189 and 190:
schedules 7. The information requir
Page 191 and 192:
alance sheet abstract and company
Page 193 and 194:
eddy pharmaceuticals hong kong ltd.
Page 195 and 196:
eport of the auditors ERNST & YOUNG
Page 197 and 198:
profit and loss account | YEAR ENDE
Page 199 and 200:
notes to financial statements - DEC
Page 201 and 202:
notes to financial statements - DEC
Page 203 and 204:
eddy biomed ltd.
Page 205 and 206:
eport of sinay joint-stock company
Page 207 and 208:
alance sheet | AS AT DECEMBER 31 (R
Page 209 and 210:
eddy antilles n.v.
Page 211 and 212:
alance sheet | AS AT DECEMBER 31 (U
Page 213 and 214:
notes to the financial statements G
Page 215 and 216:
dr. reddy’s farmacêutica do bras
Page 217 and 218:
dr. reddy’s laboratories, inc.
Page 219 and 220:
alance sheet | AS AT MARCH 31 (US $
Page 221 and 222:
statement of cash flows | FOR THE Y
Page 223 and 224:
notes to the financial statements n
Page 225 and 226:
notes to the financial statements n
Page 227 and 228:
eddy pharmaceuticals singapore pte
Page 229 and 230:
9. DIVIDENDS No dividend has been p
Page 231 and 232:
eport of the auditors to the member
Page 233 and 234:
profit and loss statement | FOR sta
Page 235 and 236:
notes to the financial statements -
Page 237 and 238:
notes to the financial statements -
Page 239 and 240:
eddy us therapeutics, inc
Page 241 and 242:
alance sheet | AS AT MARCH 31 (US $
Page 243 and 244:
statement of cash flows | FOR THE Y
Page 245 and 246:
notes to financial statements 2.REL
Page 247 and 248:
eddy cheminor s.a.
Page 249 and 250:
alance sheet | Euros March 31, Fisc
Page 251 and 252:
profit and loss account | FOR THE Y
Page 253 and 254:
accounting rules and methods Annexe
Page 255 and 256:
depreciation | AS Categories A Posi
Page 257 and 258:
ageing analysis of debts receivable
Page 259 and 260:
details of charges to be paid | AS
Page 261 and 262:
effect of different fiscal provisio
Page 263 and 264:
B - Agreements with Mr Luc Lamiraul
Page 265 and 266:
cheminor investments ltd.
Page 267 and 268:
Page 269 and 270:
alance sheet | AS AT MARCH 31 Parti
Page 271 and 272:
schedules forming part of balance s
Page 273 and 274:
alance sheet abstract and company
Page 275 and 276:
aurigene discovery technologies ltd
Page 277 and 278:
Acknowledgements The Directors take
Page 279 and 280:
annexure to the auditors’ report
Page 281 and 282:
profit and loss account | FOR EXPEN
Page 283 and 284:
schedules forming part of the profi
Page 285 and 286:
schedules forming part of the balan
Page 287 and 288:
zenovus biotech pvt. ltd.
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
kunshan rotam reddy pharmaceutical
Page 297 and 298:
alance sheet | AS AT DECEMBER 31 (R
Page 299 and 300:
income statement | FOR THE YEAR END
Page 301 and 302:
notes to the financial statements 5
Page 303 and 304:
eddy netherlands b.v.
Page 305 and 306:
alance sheet | AS AT DECEMBER 31 (I
Page 307 and 308:
general notes GENERAL COMMENTS The
Page 309 and 310:
notice
Page 311 and 312:
The remuneration payable by way of
Page 313 and 314:
Item No. 9 The Company had appointe
show all

DRIVIN G ROWTH - Dr. Reddy's

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?